In the past year, great advances have been made in the management of benign prostatic hyperplasia (BPH). To commemorate all these advances, Urology Times® will feature his top BPH content of 2023.
FDA approves Optilume BPH system
In July 2023, the FDA approved the Optilume BPH Catheter System for the treatment of lower urinary tract symptoms (LUTS) secondary to BPH. The Optilume BPH System is a minimally invasive surgical treatment consisting of a drug-coated (paclitaxel) balloon system. This approval was based on results from the PINNACLE (NCT04131907) and EVEREST (NCT03423979) trials, which demonstrated the treatment’s sustained efficacy and safety in patients with BPH-related LUTS. Please see here for the detail.
AUA releases revised guidelines on BPH-related LUTS and testicular cancer
In September 2023, the American Urological Association released the revised 2023 Clinical Practice Guidelines for the management of LUTS secondary to benign prostatic hyperplasia. This amendment is an update to the 2021 guidelines regarding conditions. Please see here for the detail.
Current practice patterns of benign prostatic hyperplasia influenced by surgeon factors
Research published in Urology found an association between surgeon factors and the use of specific surgical approaches to manage benign prostatic hyperplasia. Specifically, the researchers found that surgeon age, patient age, and urologist specialty were associated with the use of certain approaches. Click here to learn more about the survey results.
NICE in the UK recommends aquablation for benign prostatic hyperplasia
In October 2023, the UK’s National Institute for Healthcare Excellence granted aquablation its strongest endorsement, a ‘standard practice’ recommendation, for the treatment of patients with benign prostatic hyperplasia. A pivotal study supporting NICE’s recommendations is the WATER trial, which demonstrated the strong efficacy and safety of aquaablation and transurethral resection of the prostate in the treatment of men with LUTS due to benign prostatic hyperplasia. I did. Please see here for the detail.
iTind device shows durable safety and efficacy in patients with benign prostatic hyperplasia-associated LUTS
Results from the MT02 study showed that treatment with the iTind device for BPH-related LUTS led to significant and sustained reductions in symptoms and improved quality of life over 48 months after treatment.
The authors concluded, “The long-term follow-up data reported in this study demonstrate that the iTind device implant is clinically durable and is highly effective for reducing BPH-related LUTS, even in severe conditions. “We have provided evidence that it appears to be a reliable surgical tool.” “Bridge treatment”. Click here to learn more about the research results.
CMS Final Rule Increases Payment Rates for iTind Procedures in HOPDs and ASCs
The 2023 CMS Final Rule includes a payment rate increase for code C9769 that covers iTind procedures in hospital-based outpatient department (HOPD) and ambulatory surgery center (ASC) facilities. The CMS CY2023 Outpatient Prospective Payment System Rule was finalized and published on November 1, 2022, and fees became effective on January 1, 2023. Please see here for the detail.
Optilume BPH System officially launched in the global urology market
In July 2023, the world’s first patient in a commercial setting was treated with the Optilume BPH System, a minimally invasive surgical therapy used to treat LUTS secondary to BPH. The procedure was performed by urologist Dean S. Elterman, MD, MSc, FRCSC, of University Urology Associates in Toronto, Canada. Please see here for the detail.
Study highlights efficacy of prostatic artery embolization in benign prostatic hyperplasia
Research suggests that prostatic artery embolization (PAE) can promote not only short-term improvement but also sustained long-term outcomes in men with benign prostatic hyperplasia. One year after the patient underwent her PAE procedure, study authors reported a 32% reduction in prostate size. Please see here for the detail.
Aquablation safety and efficacy in benign prostatic hyperplasia maintained at 5-year follow-up
The final 5-year results of the WATER II trial (NCT03123250) showed that aquablation therapy successfully met performance goals for safety and efficacy in the management of LUTS due to benign prostatic hyperplasia. Overall, the study enrolled 101 men with moderate to severe BPH symptoms and prostate volumes between 80 mL and 150 mL. Click here to learn more about the survey results.
Cleveland Clinic shares its facility’s experience with aquablation for benign prostatic hyperplasia
Dennis Bentley, M.D., along with colleague Brian Canterbury, M.D., has spearheaded efforts to incorporate aquablation into clinical practice at the Cleveland Clinic. Learn more about our facility’s experience with this procedure.
All content related to BPH can be found here.